SARS-CoV-2 oropharyngeal viral clearance following ritonavir-boosted nirmatrelvir, molnupiravir, and no study drug
(A) Median viral loads over time in the three contemporaneous treatment groups (individual data points shown as circles). (B) The estimated treatment effects relative to ritonavir-boosted nirmatrelvir under the linear and nonlinear models (the grey zone shows the inferiority zone relative to ritonavir-boosted nirmatrelvir).